

Poster presentation

## **PII-04. PEGylated poly [2-(N,N-dimethylamino) ethyl methacrylate] as mucosal DNA delivery vector improves HIV-1-specific immune responses**

Y Qiao<sup>1</sup>, Y Huang<sup>\*2</sup>, XY Yue<sup>1</sup>, C Qiu<sup>2</sup>, LD Deng<sup>1</sup>, YM Wan<sup>2</sup>, JF Xing<sup>1</sup>, CY Zhang<sup>2</sup>, SH Yuan<sup>2</sup>, AJ Dong<sup>1</sup> and JQ Xu<sup>2</sup>

Address: <sup>1</sup>Tianjin University, Tianjin, PR China and <sup>2</sup>Science Research Center, Shanghai Public Health Clinical Center, Shanghai, PR China

\* Corresponding author

from AIDS Vaccine 2009  
Paris, France. 19–22 October 2009

Published: 22 October 2009

Retrovirology 2009, **6**(Suppl 3):P149 doi:10.1186/1742-4690-6-S3-P149

This abstract is available from: <http://www.retrovirology.com/content/6/S3/P149>

© 2009 Qiao et al; licensee BioMed Central Ltd.

### **Background**

Development of safe and efficient vectors is crucial for gene therapy and vaccine delivery. As a promising transfection reagent, poly [2-(N,N-dimethylamino) ethyl methacrylate] (PDMAEMA) have potential applications in gene delivery systems. However, its high cytotoxicity limits its advances into clinical evaluation. Polyethylene glycol (PEG) is one of the most widely used to decrease polymers' cytotoxicity in drug delivery systems. But the vaccine delivery effects was still unclear by PEGylation for this polymer.

### **Methods**

PEGylated PDMAEMA was synthesized with PEG segments by atom transfer radical polymerization, and its binding capability to DNA was determined by gel electrophore retardation assays. Its effects on transfection efficiency and cytotoxicity *in vitro* were determined by Flow Cytometry using GFP as a reporter and MTT assay respectively. Finally, ELISA and Elispot assay were used to evaluate its effects on immunogenicity as a mucosal DNA vaccine carrier *in vivo*. An plasmid DNA expressing HIV-1 gag was used as an model vaccine.

### **Results**

PEGylated PDMAEMA retained its DNA binding capability and its cytotoxicity was dramatically decreased compared to unPEGylated PDMAEMA but with low transfection efficiency *in vitro*. However, our *in vivo* data proved that

PEGylated PDMAEMA significantly improved the priming effect of an HIV DNA vaccine through intranasal administration compared to another cation vector polyethyleneimine (PEI) and had more immunostimulatory ability *in vitro*.

### **Conclusion**

Our study suggested that PEGylated PDMAEMA could be used in vaccine research as a nonviral vector and importantly, transfection efficiency *in vitro* did not correlate to the immunogenicity *in vivo* for polymer vectors especially due to its potential adjuvant effects.